Dexcom 10-Q 2024-06-30
DXCM · CIK 1093557 · Form 10-Q · Period ended June 30, 2024 · Filed July 25, 2024
Revenue rose 15.3% to $1.00 billion. Operating margin was 15.7%, against 14.7% a year earlier. Net income was $144 million.
8 sections, 192K characters. Original on sec.gov · ·
| Measure | Quarter ended Jun 30, 2024 | Quarter ended Jun 30, 2023 | Change |
|---|---|---|---|
| Revenue | $1.00B | $871M | +15.3% |
| Operating income | $158M | $128M | +23.3% |
| Net income | $144M | $116M | +23.8% |
| Diluted EPS | $0.35 | $0.28 | +25.0% |
| Cash and equivalents | $939M | n/a | n/a |
| Operating margin* | 15.7% | 14.7% | +1.0 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
| For the quarterly period ended June 30, 2024 | |||||
| or | |||||
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
| For the transition period from to |
Commission File Number: 000-51222

DEXCOM, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 33-0857544 | |||||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 6340 Sequence Drive, San Diego**,** CA | 92121 | |||||||
| (Address of principal executive offices) | (Zip Code) |
(858) 200-0200
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Common Stock, $0.001 Par Value Per Share | DXCM | Nasdaq Global Select Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☒ | Accelerated filer | ☐ | |||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||||||||||
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of July 18, 2024, there were 400,726,824 shares of the registrant’s common stock outstanding.
| DexCom, Inc. | ||
| Table of Contents |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS |
Except for historical financial information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Such statements include declarations regarding our operations, financial condition and prospects, and business strategies, and are based on management’s current intent, beliefs, expectations, and assumptions. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks, uncertainties and other factors, some of which are beyond our control; actual results could differ materially from those indicated or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to: (i) that the information is of a preliminary nature and may be subject to further adjustment; (ii) those risks and uncertainties identified under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission, or the SEC, on February 8, 2024, together with any updates identified under “Risk Factors” in our subsequent Quarterly Reports on Form 10-Q; and (iii) the other risks detailed from time-to-time in our other reports and registration statements filed with the SEC. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
| AVAILABLE INFORMATION |
Our website address is located at dexcom.com and our investor relations website is located at investors.dexcom.com. We file electronically with the SEC our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make available on our website, free of charge, copies of these reports and other information as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.
We announce material information to the public about us, our products, and other matters through a variety of means, including filings with the SEC, press releases, public conference calls, presentations, webcasts, and our investor relations website, in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. The information disclosed by the foregoing channels could be deemed to be material information. As such, we encourage investors, the media, and others to follow the channels listed above and review the information disclosed through such channels.
Except as expressly set forth in this Quarterly Report on Form 10-Q, the contents of our website and our investor relations website are not incorporated by reference into, or otherwise to be regarded as part of, this Quarterly Report on Form 10-Q or any other report or document we file with the SEC, and any references to websites are intended to be inactive textual references only.
“Dexcom”, “Dexcom Clarity”, “Dexcom One”, and other trademarks of ours appearing in this Quarterly Report on Form 10-Q are our property. Other service marks, trademarks and trade names referred to in this Quarterly Report on Form 10-Q are the property of their respective owners.
| PART I. FINANCIAL INFORMATION | ||
Item 1. FINANCIAL STATEMENTS
| DexCom, Inc. | ||
| Consolidated Balance Sheets | ||
| (Unaudited) |
| (In millions, except share and par value data) | June 30, 2024 | December 31, 2023 | |||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 939.2 | $ | 566.3 | |||||||
| Short-term marketable securities | 2,181.5 | 2,157.8 | |||||||||
| Accounts receivable, net | 945.2 | 973.9 | |||||||||
| Inventory | 570.3 | 559.6 | |||||||||
| Prepaid and other current assets | 212.2 | 168.3 | |||||||||
| Total current assets | 4,848.4 | 4,425.9 | |||||||||
| Property and equipment, net | 1,183.1 | 1,113.1 | |||||||||
| Operating lease right-of-use assets | 71.2 | 71.4 | |||||||||
| Goodwill | 23.3 | 25.2 | |||||||||
| Intangibles, net | 114.5 | 134.5 | |||||||||
| Deferred tax assets | 475.8 | 419.4 | |||||||||
| Other assets | 82.9 | 75.0 | |||||||||
| Total assets | $ | 6,799.2 | $ | 6,264.5 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and accrued liabilities | $ | 1,569.8 | $ | 1,345.5 | |||||||
| Accrued payroll and related expenses | 116.1 | 171.0 | |||||||||
| Short-term operating lease liabilities | 21.6 | 21.1 | |||||||||
| Deferred revenue | 14.7 | 18.4 | |||||||||
| Total current liabilities | 1,722.2 | 1,556.0 | |||||||||
| Long-term senior convertible notes | 2,437.8 | 2,434.2 | |||||||||
| Long-term operating lease liabilities | 76.8 | 80.1 | |||||||||
| Other long-term liabilities | 128.1 | 125.6 | |||||||||
| Total liabilities | 4,364.9 | 4,195.9 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
| Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023 | — | — | |||||||||
| Common stock, $0.001 par value, 800.0 million shares authorized; 408.5 million and 400.7 million shares issued and outstanding, respectively, at June 30, 2024; and 407.2 million and 385.4 million shares issued and outstanding, respectively, at December 31, 2023 | 0.4 | 0.4 | |||||||||
| Additional paid-in capital | 1,992.3 | 3,514.6 | |||||||||
| Accumulated other comprehensive loss | (38.0) | (16.7) | |||||||||
| Retained earnings | 1,311.3 | 1,021.4 | |||||||||
| Treasury stock, at cost; 7.8 million shares at June 30, 2024 and 21.8 million shares at December 31, 2023 | (831.7) | (2,451.1) | |||||||||
| Total stockholders’ equity | 2,434.3 | 2,068.6 | |||||||||
| Total liabilities and stockholders’ equity | $ | 6,799.2 | $ | 6,264.5 |
See accompanying notes
| DexCom, Inc. | ||
| Consolidated Statements of Operations | ||
| (Unaudited) |
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| (In millions, except per share data) | 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||
| Revenue | $ | 1,004.3 | $ | 871.3 | $ | 1,925.3 | $ | 1,612.8 | |||||||||||||||
| Cost of sales | 377.6 | 324.9 | 736.7 | 603.8 | |||||||||||||||||||
| Gross profit | 626.7 | 546.4 | 1,188.6 | 1,009.0 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 136.0 | 119.3 | 277.5 | 238.3 | |||||||||||||||||||
| Selling, general and administrative | 332.7 | 299.0 | 652.0 | 595.4 | |||||||||||||||||||
| Total operating expenses | 468.7 | 418.3 | 929.5 | 833.7 | |||||||||||||||||||
| Operating income | 158.0 | 128.1 | 259.1 | 175.3 | |||||||||||||||||||
| Other income (expense), net | 29.8 | 31.2 | 61.2 | 48.5 | |||||||||||||||||||
| Income before income taxes | 187.8 | 159.3 | 320.3 | 223.8 | |||||||||||||||||||
| Income tax expense | 44.3 | 43.4 | 30.4 | 59.3 | |||||||||||||||||||
| Net income | $ | 143.5 | $ | 115.9 | $ | 289.9 | $ | 164.5 | |||||||||||||||
| Basic net income per share | $ | 0.36 | $ | 0.30 | $ | 0.73 | $ | 0.43 | |||||||||||||||
| Shares used to compute basic net income per share | 399.2 | 386.7 | 394.8 | 386.7 | |||||||||||||||||||
| Diluted net income per share | $ | 0.35 | $ | 0.28 | $ | 0.71 | $ | 0.40 | |||||||||||||||
| Shares used to compute diluted net income per share | 416.8 | 431.5 | 416.9 | 426.6 |
See accompanying notes
| DexCom, Inc. | ||
| Consolidated Statements of Comprehensive Income | ||
| (Unaudited) |
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| (In millions) | 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||
| Net income | $ | 143.5 | $ | 115.9 | $ | 289.9 | $ | 164.5 | |||||||||||||||
| Other comprehensive income (loss), net of tax: | |||||||||||||||||||||||
| Translation adjustments and other | 0.2 | (20.2) | (19.0) | (18.8) | |||||||||||||||||||
| Unrealized gain (loss) on marketable debt securities | (0.9) | (2.6) | (2.3) | 1.1 | |||||||||||||||||||
| Total other comprehensive loss, net of tax | (0.7) | (22.8) | (21.3) | (17.7) | |||||||||||||||||||
| Comprehensive income | $ | 142.8 | $ | 93.1 | $ | 268.6 | $ | 146.8 |
See accompanying notes
**Table of [Contents](#i55c3e3c4dfc846f2a5e822
Showing the first 8K of 105K characters. Open the full section
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Quarterly Report on Form 10-Q, including the following Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future. These forward-looking statements fall within the meaning of the federal securities laws that relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements are made as of the date of this Quarterly Report on Form 10-Q, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward looking statements. The risks and uncertainties that could cause actual results to differ materially are more fully described under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on February 8, 2024, together with any updates identified under “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q, elsewhere in this Quarterly Report on Form 10-Q, and in our other reports filed with the SEC. We assume no obligation to update any of the forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform these forward-looking statements to actual results. You should read the following discussion and analysis together with our consolidated financial statements and related notes in Part I, Item 1 of this Quarterly Report on Form 10-Q.
| Overview |
| Who We Are | |||||
| We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation system, the Dexcom G6*®* integrated Continuous Glucose Monitoring System, or G6, in 2018, and we launched the Dexcom G7®, or G7, in 2023. In March 2024, we received marketing clearance from the FDA on Stelo, our new 15-day sensor designed for people with Type 2 diabetes who do not use insulin, as the first glucose biosensor that does not require a prescription. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries. |
| Global Presence | |||||
| We have built a direct sales organization in North America and certain international markets to call on health care professionals, such as endocrinologists, physicians and diabetes educators, who can educate and influence patient adoption of continuous glucose monitoring. To complement our direct sales efforts, we have entered into distribution arrangements in North America and several international markets that allow distributors to sell our products. | |||||
| Future Developments | |||||
| Product Development: We plan to develop future generations of technologies that are focused on improved performance and convenience and that will enable intelligent insulin administration. Over the longer term, we plan to continue to develop and improve networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices. We also intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior. | |||||
| Partnerships: We also continue to pursue and support development partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems. | |||||
| New Opportunities: We are also exploring how to extend our offerings to other opportunities, including for people with Type 2 diabetes that are non-insulin using, people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting. Eventually, we may apply our technological expertise to products beyond glucose monitoring. | |||||
| Critical Accounting Estimates |
The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as the reported revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
We believe that the estimates, assumptions and judgments involved in the accounting policies described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. There were no material changes to our critical accounting estimates during the six months ended June 30, 2024.
| Overview of Financial Results | ||||||||||||||||||||||||||||||||||||||
| The most important financial indicators that we use to assess our business are revenue, gross profit, operating income, net income, and operating cash flow. | ||||||||||||||||||||||||||||||||||||||
| Key Highlights for the Three Months Ended June 30, 2024 include the following: | ||||||||||||||||||||||||||||||||||||||
| Revenue | Gross Profit | Operating Income | Net Income | Operating Cash Flow | ||||||||||||||||||||||||||||||||||
| $1.00 billion | $626.7 million | $158.0 million | $143.5 million | $279.4 million | ||||||||||||||||||||||||||||||||||
| up 15% from the same period 2023 | up 15% from the same period 2023 | up 23% from the same period 2023 | up 24% from the same period 2023 | up 47% from the same period 2023 |
We ended the second quarter of 2024 with cash, cash equivalents and short-term marketable securities totaling $3.12 billion.
| Results of Operations |
| Financial Overview |
| Three Months Ended June 30, 2024 Compared to Three Months Ended June 30, 2023 | |||||||||||||||||||||||||||||||||||
| Three Months Ended June 30, | 2024 - 2023 | ||||||||||||||||||||||||||||||||||
| (In millions, except per share amounts) | 2024 | % of Revenue (1) | 2023 | % of Revenue (1) | $ Change | % Change | |||||||||||||||||||||||||||||
| Revenue | $ | 1,004.3 | 100 | % | $ | 871.3 | 100 | % | $ | 133.0 | 15 | % | |||||||||||||||||||||||
| Cost of sales | 377.6 | 38 | % | 324.9 | 37 | % | 52.7 | 16 | % | ||||||||||||||||||||||||||
| Gross profit | 626.7 | 62.4 | % | 546.4 | 62.7 | % | 80.3 | 15 | % | ||||||||||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||||||||||||||
| Research and development | 136.0 | 14 | % | 119.3 | 14 | % | 16.7 | 14 | % | ||||||||||||||||||||||||||
| Selling, general and administrative | 332.7 | 33 | % | 299.0 | 34 | % | 33.7 | 11 | % | ||||||||||||||||||||||||||
| Total operating expenses | 468.7 | 47 | % | 418.3 | 48 | % | 50.4 | 12 | % | ||||||||||||||||||||||||||
| Operating income | 158.0 | 16 | % | 128.1 | 15 | % | 29.9 | 23 | % | ||||||||||||||||||||||||||
| Other income (expense), net | 29.8 | 3 | % | 31.2 | 4 | % | (1.4) | (4) | % | ||||||||||||||||||||||||||
| Income before income taxes | 187.8 | 19 | % | 159.3 | 18 | % | 28.5 | 18 | % | ||||||||||||||||||||||||||
| Income tax expense | 44.3 | 4 | % | 43.4 | 5 | % | 0.9 | 2 | % | ||||||||||||||||||||||||||
| Net income | $ | 143.5 | 14 | % | $ | 115.9 | 13 | % | $ | 27.6 | 24 | % | |||||||||||||||||||||||
| Basic net income per share | $ | 0.36 | ** | $ | 0.30 | ** | $ | 0.06 | 20 | % | |||||||||||||||||||||||||
| Diluted net income per share | $ | 0.35 | ** | $ | 0.28 | ** | $ | 0.07 | 25 | % | |||||||||||||||||||||||||
| (1) The sum of the individual percentages may not equal the total due to rounding. | |||||||||||||||||||||||||||||||||||
| ** Not meaningful |
Revenue
We generate our revenue from the sale of disposable sensors and our reusable transmitter and receiver, collectively referred to as Reusable Hardware. We expect that the revenue we generate from the sales of our products will fluctuate from quarter to quarter. We typically experience seasonality, with lower sales in the first quarter of each year compared to the immediately preceding fourth quarter. This seasonal sales pattern relates to U.S. annual insurance deductible resets and unfunded flexible spending accounts.
Cost of sales
Cost of sales includes direct labor and materials costs related to each product sold or produced, including assembly, test labor and scrap, as well as factory overhead supporting our manufacturing operations. Factory overhead includes facilities, material procurement and control, manufacturing engineering, quality assurance, supervision and management. These costs are primarily salary, fringe benefits, share-based compensation, facility expense, supplies and purchased services. All of our manufacturing costs are included in cost of sales. In addition, amortization of certain licensing related intangibles are also included in cost of sales.
Research and development
Our research and development expenses primarily consist of engineering and research expenses related to our sensing technology, clinical trials, regulatory expenses, quality assurance programs, employee compensation, and business process outsourcers.
Selling, general and administrative
Our selling, general and administrative expenses primarily consist of employee compensation for our executive, financial, sales, marketing, information technology and administrative functions. Other significant expenses include commissions, marketing and advertising, IT software license costs, insurance, professional fees for our outside legal counsel and independent auditors, litigation expenses, patent application expenses and consulting expenses.
Other income (expense), net
Other income (expense), net consists primarily of interest and dividend income on our cash, cash equivalents and short-term marketable securities portfolio, foreign currency transaction gains and losses due to the effects of foreign currency fluctuations, realized and unrealized gains and losses on equity investments, and interest expense related to our senior convertible notes.
| Three Months Ended June 30, 2024 Compared to Three Months Ended June 30, 2023 |

| Three Months Ended June 30, | 2024 - 2023 | |||||||||||||||||||||||||||||||||||||
| 2024 | 2023 | Change in Revenue | ||||||||||||||||||||||||||||||||||||
| (In millions) | Revenue | % of Total | Revenue | % of Total | $ | % | ||||||||||||||||||||||||||||||||
| United States | $ | 731.9 | 73% | $ | 616.6 | 71% | $ | 115.3 | 19% | |||||||||||||||||||||||||||||
| International | 272.4 | 27% | 254.7 | 29% | 17.7 | 7% | ||||||||||||||||||||||||||||||||
| Total Revenue | $ | 1,004.3 | 100% | $ | 871.3 | 100% | $ | 133.0 | 15% |
| Three Months Ended June 30, 2024 Compared to Three Months Ended June 30, 2023 | ||||||||||||||||||||||||||||||||||||||
| Revenue | The revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base. We added approximately 600,000 net users to our worldwide customer base in 2023. Disposable sensor and other revenue comprised approximately 94% of total revenue and Reusable Hardware revenue comprised approximately 6% of total revenue for the three months ended June 30, 2024. Disposable sensor and other revenue comprised approximately 89% of total revenue and Reusable Hardware revenue comprised approximately 11% of total revenue for the three months ended June 30, 2023. | |||||||||||||||||||||||||||||||||||||
| Cost of sales & Gross profit | Cost of sales and gross profit increased primarily due to an increase in sales volume driven by the addition of approximately 600,000 net users to our worldwide customer base in 2023. The decrease in gross profit margin percentage in the second quarter of 2024 compared to the second quarter of 2023 was primarily driven by product and channel mix changes. |
| Three Months Ended June 30, 2024 Compared to Three Months Ended June 30, 2023 | ||||||||
| Research and development expense | Research and development expense increased primarily due to $7.3 million in compensation-related costs most notably due to higher headcount, and $3.0 million in clinical trials costs. We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy. | |||||||
| Selling, general and administrative expense | Selling, general and administrative expense increased primarily due to $15.5 million in advertising and marketing costs, $8.9 million in compensation-related costs most notably due to higher headcount, and $8.7 million in software and data costs. | |||||||
| Income tax expense | Our annual effective tax rate from normal, recurring operations decreased from 23.8% to 23.1% during the three months ended June 30, 2024 primarily due to impacts of foreign operations. There were no significant discrete items recognized during the three months ended June 30, 2024. The income tax expense recorded for the three months ended June 30, 2023 was primarily attributable to income tax expense from normal, recurring operations. The decrease in our effective tax rate for the three months ended June 30, 2024 compared to the same period in 2023 is primarily attributable to impacts of the prior year tax restructuring. |
| Results of Operations | ||||||||||||||
| Financial Overview |
| Six Months Ended June 30, 2024 Compared to Six Months Ended June 30, 2023 | |||||||||||||||||||||||||||||||||||
| Six Months Ended June 30, | 2024 - 2023 | ||||||||||||||||||||||||||||||||||
| (In millions, except per share amounts) | 2024 | % of Revenue (1) | 2023 | % of Revenue (1) | $ Change | % Change | |||||||||||||||||||||||||||||
| Revenue | $ | 1,925.3 | 100 | % | $ | 1,612.8 | 100 | % | $ | 312.5 | 19 | % | |||||||||||||||||||||||
| Cost of sales | 736.7 | 38 | % | 603.8 | 37 | % | 132.9 | 22 | % | ||||||||||||||||||||||||||
| Gross profit | 1,188.6 | 61.7 | % | 1,009.0 | 62.6 | % | 179.6 | 18 | % | ||||||||||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||||||||||||||
| Research and development | 277.5 | 14 | % | 238.3 | 15 | % | 39.2 | 16 | % | ||||||||||||||||||||||||||
| Selling, general and administrative | 652.0 | 34 | % | 595.4 | 37 | % | 56.6 | 10 | % | ||||||||||||||||||||||||||
| Total operating expenses | 929.5 | 48 | % | 833.7 | 52 | % | 95.8 | 11 | % | ||||||||||||||||||||||||||
| Operating income | 259.1 | 13 | % | 175.3 | 11 | % | 83.8 | 48 | % | ||||||||||||||||||||||||||
| Other income (expense), net | 61.2 | 3 | % | 48.5 | 3 | % | 12.7 | 26 | % | ||||||||||||||||||||||||||
| Income before income taxes | 320.3 | 17 | % | 223.8 | 14 | % | 96.5 | 43 | % | ||||||||||||||||||||||||||
| Income tax expense | 30.4 | 2 | % | 59.3 | 4 | % | (28.9) | (49) | % | ||||||||||||||||||||||||||
| Net income | $ | 289.9 | 15 | % | $ | 164.5 | 10 | % | $ | 125.4 | 76 | % | |||||||||||||||||||||||
| Basic net income per share | $ | 0.73 | ** | $ | 0.43 | ** | $ | 0.30 | 70 | % | |||||||||||||||||||||||||
| Diluted net income per share | $ | 0.71 | ** | $ | 0.40 | ** | $ | 0.31 | 78 | % | |||||||||||||||||||||||||
| (1) The sum of the individual percentages may not equal the total due to rounding. | |||||||||||||||||||||||||||||||||||
| ** Not meaningful |
| Six Months Ended June 30, 2024 Compared to Six Months Ended June 30, 2023 |

| Six Months Ended June 30, | 2024 - 2023 | |||||||||||||||||||||||||||||||||||||
| 2024 | 2023 | Change in Revenues | ||||||||||||||||||||||||||||||||||||
| (In millions) | Revenue | % of Total | Revenue | % of Total | $ | % | ||||||||||||||||||||||||||||||||
| United States | $ | 1,385.1 | 72% | $ | 1,142.6 | 71% | $ | 242.5 | 21% | |||||||||||||||||||||||||||||
| International | 540.2 | 28% | 470.2 | 29% | 70.0 | 15% | ||||||||||||||||||||||||||||||||
| Total Revenue | $ | 1,925.3 | 100% | $ | 1,612.8 | 100% | $ | 312.5 | 19% |
| Six Months Ended June 30, 2024 Compared to Six Months Ended June 30, 2023 | ||||||||
| Revenue | The revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base. We added approximately 600,000 net users to our worldwide customer base in 2023. Disposable sensor and other revenue comprised approximately 94% of total revenue and Reusable Hardware revenue comprised approximately 6% of total revenue for the six months ended June 30, 2024. Disposable sensor and other revenue comprised approximately 89% of total revenue and Reusable Hardware revenue comprised approximately 11% of total revenue for the six months ended June 30, 2023. | |||||||
| Cost of sales & Gross profit | Cost of sales and gross profit increased primarily due to an increase in sales volume driven by the addition of approximately 600,000 net users to our worldwide customer base in 2023. The decrease in gross profit margin percentage in 2024 compared to 2023 was primarily driven by product and channel mix changes. |
| Six Months Ended June 30, 2024 Compared to Six Months Ended June 30, 2023 | ||||||||
| Research and development expense | Research and development expense increased primarily due to $14.1 million in compensation-related costs most notably due to higher headcount, $6.2 million in clinical trials costs, and $5.9 million in supplies and other support costs. We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy. | |||||||
| Selling, general and administrative expense | Selling, general and administrative expense increased primarily due to $24.9 million in compensation-related costs most notably due to higher headcount, $9.6 million in software and data costs, and $8.7 million in travel related expenses. | |||||||
| Other income (expense), net | Other income (expense), net, increased primarily due to $12.8 million in interest and dividend income on our cash, cash equivalents, and marketable securities portfolio. The increase in interest income was primarily related to a change in market interest rates. | |||||||
| Income tax expense | The income tax expense recorded for the six months ended June 30, 2024 was primarily attributable to income tax expense from normal, recurring operations at an estimated annual effective tax rate of 23.1%, partially offset by discrete excess tax benefits recognized for share-based compensation for employees, net of nondeductible executive compensation, and the Verily milestone payment. The income tax expense recorded for the six months ended June 30, 2023 was primarily attributable to income tax expense from normal, recurring operations, partially offset by excess tax benefits recognized for share-based compensation for employees, net of disallowed executive compensation, and generation of research and development tax credits. The decrease in our effective tax rate for the six months ended June 30, 2024 compared to the same period in 2023 is primarily attributable to impacts of the prior year tax restructuring and the Verily milestone payment. |
| Liquidity and Capital Resources |
| Overview, Capital Resources, and Capital Requirements |
Our principal sources of liquidity are our existing cash, cash equivalents and marketable securities, cash generated from operations, proceeds from our senior convertible notes issuances, and access to our Credit Facility. Our primary uses of cash have been for research and development programs, selling and marketing activities, capital expenditures, acquisitions of businesses, and debt service costs.
We expect that cash provided by our operations may fluctuate in future periods as a result of a number of factors, including fluctuations in our operating results, working capital requirements and capital deployment decisions. We have historically invested our cash primarily in U.S. dollar-denominated, investment grade, highly liquid obligations of U.S. government agencies, commercial paper, corporate debt, and money market funds. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets.
Our future capital requirements will depend on many factors, including but not limited to:
| The evolution of the international expansion of our business and the revenue generated by sales of our approved products and any future products; | Our ability to efficiently scale our operations to meet demand for our current and any future products; | The success of our research and development efforts; | |||||||||||||||||||||
| The expenses we incur in manufacturing, developing, selling and marketing our products; | The costs, timing and risks of delays of additional regulatory approvals; | The costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; | |||||||||||||||||||||
| The quality levels of our products and services; | The emergence of competing or complementary technological developments; | The terms and timing of any collaborative, licensing and other arrangements that we may establish; and | |||||||||||||||||||||
| The third-party reimbursement of our products for our customers; | The rate of progress and cost of our clinical trials and other development activities; | The acquisition of businesses, products and technologies and our ability to integrate and manage any acquired businesses, products and technologies. |
We expect that existing cash and short-term investments and cash flows from our future operations will generally be sufficient to fund our ongoing core business. As current borrowing sources become due, we may be required to access the capital markets for additional funding. As we assess inorganic growth strategies, we may need to supplement our internally generated cash flow with outside sources. In the event that we are required to access the debt market, we believe that we will be able to secure reasonable borrowing rates. As part of our liquidity strategy, we will continue to monitor our current level of earnings and cash flow generation as well as our ability to access the market in light of those earning levels.
A substantial portion of our operations are located in the United States, and the majority of our sales since inception have been made in U.S. dollars. We will be exposed to additional foreign currency exchange risk related to our international operations as we expand our manufacturing internationally and as our business continues to increase in international markets. See “Foreign Currency Exchange Risk” in Part II, Item 7A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, for more information.
Main Sources of Liquidity
Cash, cash equivalents and short-term marketable securities
Our cash, cash equivalents and short-term marketable securities totaled $3.12 billion as of June 30, 2024. None of those funds were restricted and $2.93 billion (approximately 94%) of those funds were located in the United States.
Cash flow from Operations
For the six months ended June 30, 2024, we had positive cash flows of $488.6 million from operating activities. We anticipate that we will continue to generate positive cash flows from operations for the foreseeable future.
Senior Convertible Notes
We received net proceeds of $1.19 billion in May 2020 from the 2025 Notes offering, and net proceeds of $1.23 billion in May 2023 from the 2028 Notes offering. We used $282.6 million of the net proceeds from the offering of the 2025 Notes to repurchase a portion of our senior convertible notes due in 2022. We used $289.9 million of the net proceeds from the offering of the 2028 Notes to purchase capped call transactions and repurchase shares of our common stock in May 2023. We intend to use the remainder of the net proceeds from the 2025 Notes offering and 2028 Notes offering for general corporate purposes and capital expenditures, including working capital needs. We may also use the net proceeds to expand our current business through in-licensing or acquisitions of, or investments in, other businesses, products or technologies; however, we do not have any significant commitments with respect to any such acquisitions or investments at this time.
In connection with the 2028 Notes offering, we purchased the 2028 Capped Calls. See Note 5 “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information about our senior convertible notes and the 2028 Capped Calls.
Revolving Credit Agreement
As of June 30, 2024, we had no outstanding borrowings, $7.6 million in outstanding letters of credit, and a total available balance of $192.4 million under the Amended Credit Agreement. We monitor counterparty risk associated with the institutional lenders that are providing the Credit Facility. We currently believe that the Credit Facility will be available to us should we choose to borrow under it. Revolving loans will be available for general corporate purposes, including working capital and capital expenditures. See Note 5 “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information on the Revolving Credit Agreement.
Short-term Liquidity Requirements
Our short-term liquidity requirements primarily consist of regular operating costs, interest payments related to our senior convertible notes, capital expenditures for the development of our manufacturing facilities and office spaces, and short-term material cash requirements as described below. As of June 30, 2024, we had a working capital ratio of 2.82 and a quick ratio of 2.36, which indicates that our current assets are more than enough to cover our short-term liabilities. We expect to have significant capital expenditures for the next year to scale-up capacity in Mesa, Arizona and drive our strategic initiatives of building out our manufacturing facilities and/or equipment in Malaysia and Ireland.
We believe that our cash, cash equivalents, and marketable securities balances, projected cash contributions from our commercial operations, and borrowings under our Credit Facility will be sufficient to meet our anticipated seasonal working capital needs, all capital expenditure requirements, material cash requirements as described below, and other liquidity requirements associated with our operations for at least the next 12 months. We may use cash to repurchase shares of our common stock, including pursuant to the 2024 Share Repurchase Program, or for other strategic initiatives that strengthen our foundation for long-term growth.
Long-term Liquidity Requirements
Our long-term liquidity requirements primarily consist of interest and principal payments related to our senior convertible notes, capital expenditures for the development of our manufacturing facilities and office spaces, and long-term material cash requirements as described below. As of June 30, 2024, we had a debt-to-assets ratio of 0.36, which indicates that our total assets are more than enough to cover our short-term and long-term debts. As demand grows for our products, we will continue to expand global operations to meet demand through investments in manufacturing and operations. We expect to meet our long-term liquidity requirements from our main sources of liquidity as described above to support our future operations, capital expenditures, acquisitions, and other liquidity requirements associated with our operations beyond the next 12 months.
As of June 30, 2024, we have outstanding senior convertible notes that will mature in November 2025 and May 2028. However, the outstanding principal of our senior convertible notes could be converted into cash and/or shares of our common stock prior to maturity once certain conditions are met. See Note 5 “Debt—Senior Convertible Notes” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for information on conversion rights prior to maturity.
Material Cash Requirements
From time to time in the ordinary course of business, we enter into a variety of purchase arrangements including but not limited to, purchase arrangements related to capital expenditures, components used in manufacturing, and research and development activities. See “Contractual Obligations” below for more information.
Our obligations under the 2025 Notes and 2028 Notes include both principal and interest payments. Although the 2025 Notes and 2028 Notes mature in November 2025 and May 2028, respectively, they may be converted into cash and/or shares of our common stock prior to maturity if certain conditions are met. Any conversion prior to maturity may result in repayment of the principal amounts due under the Notes sooner than the scheduled repayment.
As market conditions warrant, we may, from time to time, repurchase our outstanding debt securities or shares of our common stock, including pursuant to the 2024 Share Repurchase Program, in the open market, in privately negotiated transactions, by exchange transaction or otherwise. Such repurchases, if any, will depend on prevailing market conditions, our liquidity and other factors and may be commenced or suspended at any time. The amounts involved and total consideration paid may be material. See Note 10 “Subsequent Events” for more information about the 2024 Share Repurchase Program.
See Note 5 “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information about the terms of the Amended Credit Agreement, our senior convertible notes, and the 2028 Capped Calls.
We are party to various leasing arrangements, primarily for office, manufacturing and warehouse space that expire at various times through December 2030, excluding any renewal options. We also have land leases in Penang, Malaysia that expire in 2082 and Athenry, Ireland that expire in 3023 for our international manufacturing facilities. We anticipate incurring significant expenditures related to our Malaysia manufacturing facility and equipment over the next year and the build-out of the Ireland manufacturing facility and equipment over the next five years. See Note 6 “Leases and Other Commitments—Leases” to the consolidated financial statements in Part II, Item 8 of our Annual Report for the fiscal year ended December 31, 2023 for more information about our leases.
| Cash Flows | ||
The following table sets forth a summary of our cash flows for the periods indicated. See the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for the complete consolidated statements of cash flows for these periods.

As of June 30, 2024, we had $3.12 billion in cash, cash equivalents and short-term marketable securities, which is an increase of $396.6 million compared to $2.72 billion as of December 31, 2023.
The primary cash flows during the six months ended June 30, 2024 and June 30, 2023 are described below. See the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for complete consolidated statements of cash flows for these periods.
| Six Months Ended | ||||||||||||||||||||
| June 30, 2024 | June 30, 2023 | |||||||||||||||||||
| Operating Cash Flows | + | $289.9 million of net income, $112.1 million of net non-cash adjustments, and a net increase of $86.6 million in changes of working capital balances | + | $164.5 million of net income, $82.9 million of net non-cash adjustments, and a net increase of $98.3 million in changes of working capital balances | ||||||||||||||||
| Net non-cash adjustments were primarily related to depreciation and amortization, share-based compensation, and deferred income taxes | Net non-cash adjustments were primarily related to depreciation and amortization and share-based compensation | |||||||||||||||||||
| Investing Cash Flows | + | $12.0 million in net proceeds from marketable securities | - | $592.9 million in net purchases of marketable securities | ||||||||||||||||
| - | $123.0 million in capital expenditures | - | $133.7 million in capital expenditures | |||||||||||||||||
| - | $16.0 million in purchases of equity investments | |||||||||||||||||||
| Financing Cash Flows | + | $13.4 million in proceeds from issuance of common stock under our employee stock plans | + | $1.23 billion in proceeds from issuance of senior convertible notes, net of issuance costs | ||||||||||||||||
| - | $10.1 million in payments for financing leases | + | $12.3 million in proceeds from issuance of common stock under our employee stock plans | |||||||||||||||||
| - | $188.7 million in purchases of treasury stock | |||||||||||||||||||
| - | $101.3 million in purchases of capped call transactions |
| Contractual Obligations |
We presented our contractual obligations as of December 31, 2023 in Note 6 “Leases and Other Commitments” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. There were no material changes to our lease or contractual obligations outside the ordinary course of business during the six months ended June 30, 2024. See Note 5 “Debt—Senior Convertible Notes” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information on our senior convertible notes.
| Recent Accounting Guidance |
See Note 1 “Organization and Significant Accounting Policies” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information regarding recently issued accounting pronouncements and the potential impact on our consolidated financial statements, if any.
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There were no material changes to our quantitative and qualitative disclosures about market risk during the six months ended June 30, 2024. See Part II, Item 7A “Quantitative and Qualitative Disclosures about Market Risk” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, for a detailed discussion of our market risks.
Item 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Regulations under the Exchange Act require public companies to maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Disclosure controls and procedures include, without limitation, controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and timely communicated to management, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on their evaluation as of June 30, 2024, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of such date.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitation on Effectiveness of Controls
It should be noted that any system of controls, including ours, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. The design of any control system is based, in part, upon the benefits of the control system relative to its costs. Control systems can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. In addition, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these and other inherent limitations of control systems, we cannot guarantee that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.
| PART II. OTHER INFORMATION |
| Item 1. LEGAL PROCEEDINGS |
We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment related matters.
Since June 2021, we and certain Abbott Diabetes Care, Inc. (“Abbott”) entities have served patent infringement complaints against each other in multiple jurisdictions against certain continuous glucose monitoring products of each company.
In June 2021, we initiated patent infringement litigation against Abbott in the United States (U.S.D.C., Western District of Texas) and Germany (National Court (“N.C.”) in Mannheim). In May 2023, we filed additional patent infringement actions in Germany (N.C. in Munich). In July and August 2023, we initiated patent infringement litigation in the United Patent Court (“UPC”) (Paris & Munich) and in Spain (Commercial Courts of Barcelona). On July 4, 2024, after a hearing on May 24, 2024, the Paris division of the UPC issued its decision revoking our patent asserted against Abbott. We currently await a ruling from the June 4, 2024 hearing in the Munich division of the UPC on a different Dexcom patent.
In October and November 2023, we initiated patent infringement litigation in Germany (N.C. in Munich) and in the UPC (Paris & Munich). In January 2024, we initiated patent infringement litigation in Germany (N.C. in Hamburg).
In July 2021, one day after we initiated litigation in the U.S.D.C., Western District of Texas, Abbott initiated patent infringement litigation against Dexcom in the United States (U.S.D.C., Delaware (“D1”)). Shortly thereafter, Abbott filed additional patent infringement litigation actions in the United Kingdom (Business and Property Courts of England and Wales) and Germany (N.C. in Mannheim and Dusseldorf).
In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in the Business and Property Courts of England and Wales. Three trials on liability have already been conducted in the United Kingdom. On October 18, 2023 and June 28, 2024, judgment was handed down in favor of Dexcom, finding the Abbott patents to be invalid and not infringed. On January 15, 2024, judgment was handed down invalidating both Abbott and Dexcom’s patents.
In December 2021, Abbott filed a breach of contract lawsuit against Dexcom in the United States (U.S.D.C., District of Delaware) alleging that Dexcom breached the parties' Settlement and License Agreement dated July 2, 2014 (“SLA”). The U.S.D.C., District of Delaware consolidated Abbott’s breach of contract lawsuit with Dexcom’s patent infringement lawsuit which had been transferred from the U.S.D.C., Western District of Texas (“D3”). Dexcom asserted counterclaims that Abbott also breached the SLA. A jury trial on Abbott’s breach of contract claims commenced on July 10, 2023. On July 14, 2023, the jury verdict determined that Abbott was not licensed to thirteen claims of certain Dexcom patents and that Abbott was licensed to five claims. In April 2022, Abbott initiated the inter partes review (“IPR”) process on the asserted claims of Dexcom’s patents in D3. The U.S. Patent and Trademark Office (the “PTO”) denied institution of one of Dexcom’s patents and instituted IPR on the other four. Ultimately, in November 2023, the PTO issued its Final Written Decision, upholding claims of two Dexcom patents to be patentable, which cover factory calibration and certain alarms and alerts, and two to be unpatentable, which cover certain sensor code and sensor configurations. We will continue to enforce the remaining claims of the patents asserted in Delaware.
In February 2023, Abbott filed patent infringement litigation against us in Germany (N.C. in Hamburg and Munich). In March 2023, Abbott filed a patent infringement litigation in the United States (U.S.D.C., Delaware (“D4”)) and we filed counterclaims for patent infringement in that action in June 2023. In June 2023, Abbott filed patent infringement litigation actions in the United Kingdom (Business and Property Courts of England and Wales). In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in that jurisdiction. Two trials are set to occur in the United Kingdom in late 2024 and early 2025, with two Dexcom patents asserted and one Abbott patent asserted.
Abbott’s patent infringement trial, “D1”, against Dexcom commenced in the U.S.D.C., District of Delaware in March 2024. In the lead up to trial, the U.S.D.C., District of Delaware invalidated one of Abbott’s patents on factory calibration and Abbott dropped four other patents from the litigation. The claims litigated were isolated to the inserter mechanism and the wearable seal and mount of Dexcom’s G6. On March 22, 2024, a jury returned a mixed verdict. The jury found that Dexcom infringes one patent, that Dexcom did not infringe a second patent, and that Dexcom also did not infringe a third patent, which the jury also found invalid. The jury found that any infringement was not willful. It could not reach unanimity as to a fourth patent. No determination of damages was made or awarded. Dexcom will challenge the sole finding of infringement and continue to defend itself vigorously.
Commencing in January 2024, patent infringement hearings between Abbott and Dexcom were scheduled to take place wherein each sought damages and injunctive relief against the other. All but one of Abbott’s offensive hearings were either stayed or cancelled entirely due to parallel invalidity proceedings and nullity decisions. After a February 28, 2024 hearing in Munich wherein Abbott asserted patent infringement claims against Dexcom, Dexcom received a favorable non-infringement decision. On July 24, 2024, Dexcom received a decision from the Munich court related to the July 3, 2024 hearing, staying our offensive infringement proceedings pending the outcome of an opposition proceeding. Dexcom currently awaits decisions from the Court in Munich on two separate offensive patent infringement matters which were heard on April 17 and April 24, 2024.
Due to uncertainty surrounding patent litigation procedures initiated by Dexcom and Abbott throughout multiple jurisdictions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time. We intend to protect our intellectual property and defend against Abbott’s claims vigorously in all of these actions.
We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition, or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition, or results of operations.
Item 1A. RISK FACTORS
The following risk factor supplements and, to the extent inconsistent, supersedes, the risk factors disclosed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 8, 2024. Our short and long-term success is subject to numerous risks and uncertainties, many of which involve factors that are difficult to predict or beyond our control. Before making a decision to invest in, hold or sell our common stock, stockholders and potential stockholders should carefully consider the risks and uncertainties described herein and in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which could materially and adversely affect our business, financial condition, results of operations and prospects. In that case, the value of our common stock could decline and stockholders may lose all or part of their investment.
Furthermore, additional risks and uncertainties of which we are currently unaware, or which we currently consider to be immaterial, could have a material adverse effect on our business, financial condition, results of operations or prospects. Refer to our disclaimer regarding forward-looking statements at the beginning of Part I, Item 1 of this Quarterly Report on Form 10-Q.
We cannot guarantee that the 2024 Share Repurchase Program will be fully consummated or that such program will enhance the long-term value of our share price.
In July 2024, our Board of Directors authorized and approved the 2024 Share Repurchase Program, which provides for the repurchase of up to $750.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2025. Repurchases of our common stock under the 2024 Share Repurchase Program may be made from time to time in the open market, in privately negotiated transactions or by other methods, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, at our discretion, and in accordance with the limitations set forth in Rule 10b-18 promulgated under the Exchange Act and other applicable federal and state laws and regulations. The timing of any repurchases will depend on market conditions and will be made at our discretion. The 2024 Share Repurchase Program does not obligate us to repurchase any dollar amount or number of shares of our common stock, and the program may be extended, modified, suspended, or discontinued at any time.
The 2024 Share Repurchase Program could affect the price of our common stock and increase the volatility thereof. Price volatility may cause the average price at which we repurchase our common stock in a given period to exceed the stock’s price at a given point in time. There can be no assurance that the timeframe for repurchases under our 2024 Share Repurchase Program or that any repurchases conducted thereunder will have a positive impact on our stock price or earnings per share. Important factors that could cause us to discontinue or decrease share repurchases under the 2024 Share Repurchase Program include, among others, unfavorable market conditions; the market price of our common stock; the nature of other investment or strategic opportunities presented to us from time to time; our ability to make appropriate, timely, and beneficial decisions as to when, how, and whether to repurchase shares under the 2024 Share Repurchase Program; and the availability of funds necessary to fulfill such repurchases.
| Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
None.
| Item 3. DEFAULTS UPON SENIOR SECURITIES |
None.
| Item 4. MINE SAFETY DISCLOSURES |
None.
Item 5. OTHER INFORMATION
Item 6. EXHIBITS
| Incorporated by Reference | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Exhibit Number | Exhibit Description | Form | File No. | Date of First Filing | Exhibit Number | Provided Herewith | ||||||||||||||||||||||||||||||||||||||||||||
| 31.01 | Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a). | — | — | — | — | X | ||||||||||||||||||||||||||||||||||||||||||||
| 31.02 | Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a). | — | — | — | — | X | ||||||||||||||||||||||||||||||||||||||||||||
| 32.01** | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b). | — | — | — | — | X | ||||||||||||||||||||||||||||||||||||||||||||
| 32.02** | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b). | — | — | — | — | X | ||||||||||||||||||||||||||||||||||||||||||||
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | X | ||||||||||||||||||||||||||||||||||||||||||||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||||||||||||||||||||||||||||||||||||||||||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||||||||||||||||||||||||||||||||||||||||||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||||||||||||||||||||||||||||||||||||||||||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | ||||||||||||||||||||||||||||||||||||||||||||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | ||||||||||||||||||||||||||||||||||||||||||||||||
| 104 | Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 is formatted in Inline XBRL | X |
| ** | This certification is not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that Dexcom specifically incorporates it by reference. |
| SIGNATURES |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| DEXCOM, INC. (Registrant) | |||||||||||||||||
| Dated: | July 25, 2024 | By: | /s/ KEVIN R. SAYER | ||||||||||||||
| Kevin R. Sayer, Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer) | |||||||||||||||||
| Dated: | July 25, 2024 | By: | /s/ JEREME M. SYLVAIN | ||||||||||||||
| Jereme M. Sylvain, Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) |